The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging

G. A. Ricaurte, L. E. DeLanney, K. T. Finnegan, I. Irwin, J. W. Langston

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The dopamine-depleting effects of intracerebroventricularly administered 6-hydroxydopamine (6-OHDA) were studied in young mature (6-8 weeks), older (8-12 months) and aged (18-24 months) mice. No differences were noted between age groups. To rule out the possibility that higher levels of monoamine oxidase (which degrades 6-OHDA) in older animals might be masking an increased sensitivity of older neurons to 6-OHDA, experiments were repeated after treatment with pargyline (50 mg/kg). Again, no differences between age groups were noted. We conclude that aging does not increase the sensitivity of dopaminergic neurons to 6-OHDA.

Original languageEnglish (US)
Pages (from-to)395-398
Number of pages4
JournalBrain research
Issue number1-2
StatePublished - Jan 12 1988


  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
  • 6-Hydroxydopamine
  • Dopamine
  • Neurotoxicity
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology


Dive into the research topics of 'The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging'. Together they form a unique fingerprint.

Cite this